{"id":1392,"date":"2026-09-17T20:37:14","date_gmt":"2026-09-17T12:37:14","guid":{"rendered":"http:\/\/www.puriactives.com\/en\/?p=1392"},"modified":"2026-09-17T20:37:14","modified_gmt":"2026-09-17T12:37:14","slug":"nanoactive-azelaic-acid-50","status":"publish","type":"post","link":"http:\/\/www.puriactives.com\/en\/?p=1392","title":{"rendered":"NanoActive™ Azelaic Acid 50%"},"content":{"rendered":"

ENGLISH VERSIONComplete English Article<\/h2>\n

PURIPHARM CO., LTD. \u00b7 TECHNICAL PRESENTATION \u00b7 COSMETIC ACTIVE INGREDIENT<\/p>\n

NANOACTIVE™ SERIES \u00b7 NANO-ENCAPSULATED ACTIVES<\/p>\n

NanoActive™Azelaic Acid 50%<\/h2>\n

Nano-encapsulated Azelaic Acid 50%<\/p>\n

Multi-pathway skin clarification \u00b7 Pigment management \u00b7 Follicular clarification<\/p>\n

<\/p>\n

Abstract:<\/b> 50% high-payload azelaic acid combined with next-generation nanoliposome delivery. Four published evidence pathways\u2014keratinization regulation, microbiome clarification, inflammation modulation, and pigment management\u2014address the classic formulation paradox of an effective but difficult-to-formulate molecule.<\/p>\n

Powered by PURISOME\u00ae FlexVes™ Liposome TechnologyPuriPharm Co., Ltd.<\/p>\n

PART II \u00b7 ENGLISH VERSION<\/p>\n

POSITIONING \u00b7 PRODUCT POSITIONING<\/p>\n

Re-engineering how azelaic acid is delivered<\/h2>\n

50% high-payload azelaic acid \u00d7 next-generation nano delivery<\/b><\/p>\n

Powerful multi-pathway biology<\/p>\n

\u2193<\/p>\n

A difficult-to-formulate molecule<\/p>\n

\u2193<\/p>\n

PURISOME\u00ae nanoliposome delivery<\/p>\n

\u2193<\/p>\n

Modern azelaic acid formulation<\/p>\n

Azelaic acid has long-established value in blemish-prone skin, pigmentation, and follicular biology. Its main limitation is formulation and delivery rather than efficacy. NanoActive™ Azelaic Acid 50% addresses this classic paradox through a 50% active payload and PURISOME\u00ae nanoliposome delivery.<\/p>\n

ONE MOLECULE \u00b7 MULTIPLE PATHWAYS<\/p>\n

The multidimensional biology of azelaic acid<\/h2>\n

Azelaic acid is more than an anti-acne ingredient. It is one of the few multifunctional actives that simultaneously addresses keratinization, the microbiome, inflammation, and pigmentation pathways.<\/p>\n

01<\/p>\n

Keratinization regulation<\/h3>\n

Regulates terminal differentiation of keratinocytes in the follicular infundibulum and helps reduce follicular keratin buildup at its source.<\/p>\n

02<\/p>\n

Microbiome clarification + inflammation modulation<\/h3>\n

Interferes with intracellular bacterial protein synthesis, reduces neutrophil ROS release, and modulates inflammatory signaling.<\/p>\n

03<\/p>\n

Pigment management<\/h3>\n

Competitively inhibits tyrosinase to support the management of post-acne marks, visible hyperpigmentation, and uneven tone.<\/p>\n

04<\/p>\n

Follicular and scalp microenvironment<\/h3>\n

Published evidence of follicular accumulation extends its potential use to scalp and follicular care.<\/p>\n

Blemish-prone skin \u00b7 Abnormal keratinization \u00b7 Microbiome \u00b7 Visible inflammation \u00b7 Post-acne marks \u00b7 Uneven tone \u00b7 Oxidative stress \u00b7 Follicular and scalp care: multiple pathways addressed by one molecule.<\/p>\n

THE FORMULATION PARADOX<\/p>\n

Effective, yet difficult to formulate<\/h2>\n

\u2248 0.24%<\/p>\n

Intrinsic water solubility of azelaic acid at 20\u00b0C \u00b7 reported in the literature<\/p>\n

15\u201320%<\/p>\n

Use levels in established topical efficacy research \u00b7 historical literature and pharmaceutical products<\/p>\n

How can a high-dose, poorly soluble molecule be incorporated into an elegant modern formulation?<\/b><\/p>\n

Note: 15\u201320% refers to use levels in historical literature and pharmaceutical products. It illustrates the formulation challenge and does not represent a recommended cosmetic use level for NanoActive™ Azelaic Acid 50%.<\/p>\n

MECHANISM I \u00b7 KERATINIZATION REGULATION<\/p>\n

Keratinization regulation: reducing follicular keratin buildup at the source<\/h2>\n

Abnormal keratinocyte differentiation<\/p>\n

\u2193<\/p>\n

Follicular hyperkeratinization<\/p>\n

\u2193<\/p>\n

Microcomedone formation<\/p>\n

\u2193<\/p>\n

Comedones and clogged pores<\/p>\n

\u2193<\/p>\n

Inflammatory lesions<\/p>\n

Published evidence shows that azelaic acid has antikeratinizing activity and helps restore disrupted terminal differentiation of keratinocytes in the follicular infundibulum.<\/p>\n

    \n
  • Reduces follicular hyperkeratosis<\/li>\n
  • Decreases the number and volume of keratohyalin granules<\/li>\n
  • Improves abnormal follicular keratinization and restores terminal keratinocyte differentiation<\/li>\n<\/ul>\n

    Cosmetic value positioning:<\/b> helps reduce follicular keratin buildup at its source.<\/p>\n

    Pathological sequence in acne-prone follicles: abnormal keratinization is the starting point. Normal Follicle vs Hyperkeratinized Follicle.<\/p>\n

    PUBLISHED EVIDENCE \u00b7 HISTOLOGIC EVIDENCE OF KERATINIZATION NORMALIZATION<\/p>\n

    Marked reduction and normalization of hyperkeratosis after 8\u201312 weeks<\/h2>\n

    8\u201312 weeks<\/p>\n

    20% azelaic acid cream, applied twice dailyMarked reduction or normalization of intrafollicular and interfollicular hyperkeratosis<\/p>\n

    01<\/p>\n

    Marked reduction in hyperkeratosis<\/h3>\n

    Histologic observations showed marked improvement or normalization of both intrafollicular and interfollicular hyperkeratosis.<\/p>\n

    02<\/p>\n

    Fewer and smaller keratohyalin granules<\/h3>\n

    The number and size of keratohyalin granules decreased, indicating normalization of the keratinization process.<\/p>\n

    03<\/p>\n

    Normalization of terminal keratinocyte differentiation<\/h3>\n

    Disrupted terminal differentiation was corrected, restoring a healthier follicular keratinization pattern.<\/p>\n

    Gollnick H. Azelaic acid \u2014 pharmacology, toxicology and mechanisms of action on keratinization in vitro and in vivo. J Dermatol Treat. 1993.Published evidence on conventional azelaic acid formulations; not a finished-product clinical trial of NanoActive™ Azelaic Acid 50%.<\/p>\n

    MECHANISM II \u00b7 FOLLICULAR MICROBIOME<\/p>\n

    Follicular microbiome: antimicrobial action from within the cell<\/h2>\n

    Azelaic acid<\/p>\n

    \u2193<\/p>\n

    Transport into the bacterial cell<\/p>\n

    \u2193<\/p>\n

    Interference with intracellular protein synthesis<\/p>\n

    \u2193<\/p>\n

    Reduced microbial growth and proliferation<\/p>\n

    This is more specific than a general claim of \u201ckilling acne bacteria.\u201d Published mechanistic research indicates that azelaic acid enters bacterial cells via transport mechanisms and interferes with intracellular protein synthesis, thereby reducing microbial growth and proliferation.<\/p>\n

    01<\/p>\n

    Cutibacterium acnes<\/h3>\n

    Formerly Propionibacterium acnes; the historical name is retained when citing original publications.<\/p>\n

    02<\/p>\n

    Staphylococcus epidermidis<\/h3>\n

    A resident skin bacterium examined in microbiome-related research.<\/p>\n

    PUBLISHED EVIDENCE \u00b7 ANTIMICROBIAL ACTION<\/p>\n

    At least 96% reduction in skin-surface and follicular-associated bacteria after 8 weeks<\/h2>\n

    \u226596%<\/p>\n

    Reduction in bacteria sampled from the skin surface and follicles<\/p>\n

    20%<\/p>\n

    Azelaic acid cream<\/p>\n

    8 weeks<\/p>\n

    Topical treatment period<\/p>\n

    Surface + follicle<\/p>\n

    Two sampling levels<\/p>\n

    After 8 weeks of topical treatment with 20% azelaic acid cream, counts of propionibacteria and staphylococci on the skin surface and within follicles fell by at least 96%, demonstrating microbiome clarification that reaches into the follicle.<\/p>\n

    Holland KT, Bojar RA. Antimicrobial effects of azelaic acid. J Dermatol Treat. 1993.Published evidence using a conventional 20% azelaic acid cream; not a finished-product clinical trial of NanoActive™ Azelaic Acid 50%.<\/p>\n

    MECHANISM III \u00b7 ROS & INFLAMMATION<\/p>\n

    Reducing oxidative stress and modulating inflammatory signals<\/h2>\n

    Azelaic acid<\/p>\n

    \u2193<\/p>\n

    Reduced neutrophil ROS release<\/p>\n

    \u2193<\/p>\n

    Lower oxidative inflammatory burden<\/p>\n

    Pathway examined in published research:<\/b> CD36 \u2192 NADPH oxidase \u2192 ROS \u2192 MAPK \u2192 NF-\u03baB<\/p>\n

    The literature reports that azelaic acid can reduce reactive oxygen species generation and downregulate oxidative inflammatory cascades. Related studies also involve innate immune signaling nodes such as TLR2, KLK5, and LL-37\/cathelicidin, although the strength of evidence varies by target.<\/p>\n

    01<\/p>\n

    Soothes blemish-prone skin<\/h3>\n

    Cosmetic value<\/p>\n

    02<\/p>\n

    Supports improvement in the appearance of redness<\/h3>\n

    Cosmetic value<\/p>\n

    03<\/p>\n

    Improves the inflammatory environment around clogged follicles<\/h3>\n

    Cosmetic value<\/p>\n

    04<\/p>\n

    Supports a healthier-looking skin texture<\/h3>\n

    Cosmetic value<\/p>\n

    CLINICAL EVIDENCE \u00b7 INFLAMMATORY LESIONS<\/p>\n

    Greater reduction in inflammatory lesion counts with 15% azelaic acid gel<\/h2>\n

    <\/p>\n

      \n
    • 251 adult patients<\/li>\n
    • Moderate-to-severe papulopustular rosacea<\/li>\n
    • 15-week controlled clinical study<\/li>\n
    • 15% azelaic acid gel vs active comparator gel; the azelaic acid group had a greater mean reduction in inflammatory lesion count<\/li>\n<\/ul>\n

      This evidence supports the anti-inflammatory skin biology of azelaic acid. The comparator is described generically and no commercial brand is identified.<\/p>\n

      Elewski BE, et al. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea. Arch Dermatol. 2003;139:1444\u20131450.<\/p>\n

      MECHANISM IV \u00b7 PIGMENT CONTROL<\/p>\n

      Pigment management through competitive tyrosinase inhibition<\/h2>\n

      L-Tyrosine<\/p>\n

      \u2193<\/p>\n

      Tyrosinasecompetitively inhibited by azelaic acid<\/p>\n

      \u2193<\/p>\n

      L-DOPA<\/p>\n

      \u2193<\/p>\n

      Dopaquinone<\/p>\n

      \u2193<\/p>\n

      Melanin<\/p>\n

      Azelaic acid has been reported to competitively inhibit tyrosinase and to have specific biological relevance in hyperactive melanocyte systems. Together with reduced ROS, modulation of melanogenesis, and improvement of the post-inflammatory environment, this forms a more complete pigment-management pathway. Azelaic acid is not a bleaching agent; it is a multi-pathway pigment-management active.<\/p>\n

        \n
      • Post-acne marks<\/li>\n
      • Uneven tone<\/li>\n
      • Visible hyperpigmentation<\/li>\n
      • Management of dullness and skin clarity<\/li>\n<\/ul>\n

        CLINICAL EVIDENCE \u00b7 HYPERPIGMENTATION<\/p>\n

        20% azelaic acid: an established clinical foundation for pigment management<\/h2>\n

        <\/p>\n

          \n
        • Randomized, double-blind, controlled clinical study<\/li>\n
        • 329 female participants<\/li>\n
        • 24 weeks \u00b7 20% azelaic acid vs 4% hydroquinone<\/li>\n
        • Median reduction in lesion area: approximately 71% vs approximately 78%<\/li>\n
        • Good\/excellent overall improvement: 64.8% vs 72.5%<\/li>\n
        • No statistically significant difference between groups in overall improvement<\/li>\n<\/ul>\n

          Clinical research in melasma and other hyperpigmentation concerns shows that azelaic acid has an efficacy foundation comparable with that of a classic reference ingredient.<\/p>\n

          Gupta AK, et al. The treatment of melasma: A review of clinical trials. J Am Acad Dermatol. 2006;55:1048\u20131065.<\/p>\n

          POST-ACNE MARKS \u00b7 FROM BLEMISH TO MARK<\/p>\n

          Pigmentation may persist after the blemish resolves<\/h2>\n

          Follicular blockage<\/p>\n

          \u2193<\/p>\n

          Inflammation<\/p>\n

          \u2193<\/p>\n

          ROS \/ inflammatory mediators<\/p>\n

          \u2193<\/p>\n

          Melanocyte activation<\/p>\n

          \u2193<\/p>\n

          Post-inflammatory hyperpigmentationPIH \/ post-acne marks<\/p>\n

          Five stages addressed by azelaic acid:<\/b> keratinization, the inflammatory environment, microbiome balance, tyrosinase, and oxidative stress.<\/p>\n

          From blemish to mark: one active addresses a more complete biological pathway.<\/p>\n

          FOLLICULAR DELIVERY MATTERS \u00b7 EVIDENCE OF FOLLICULAR ACCUMULATION<\/p>\n

          The follicle is where azelaic acid needs to reach<\/h2>\n
            \n
          • Single topical application of 20% azelaic acid cream<\/li>\n
          • 9 healthy adults \u00b7 forehead and back<\/li>\n
          • Follicular casts collected over 5 hours<\/li>\n
          • Measurable accumulation of azelaic acid in the pilosebaceous unit<\/li>\n<\/ul>\n

            36\u2013251<\/p>\n

            mmol\/L \u00b7 estimated peak concentration in back follicles<\/p>\n

            2\u2013112<\/p>\n

            mmol\/L \u00b7 estimated peak concentration in forehead follicles<\/p>\n

            Follicular concentrations reached or exceeded the concentrations required to inhibit C. acnes and S. epidermidis in vitro. This provides a scientific foundation for the PURISOME\u00ae follicular-delivery concept.<\/p>\n

            Bojar RA, et al. Follicular concentrations of azelaic acid after a single topical application. Br J Dermatol. 1993;129:399\u2013402.Published data on a conventional azelaic acid formulation; not a NanoActive™ Azelaic Acid 50% product study.<\/p>\n

            WHY NANO DELIVERY MATTERS<\/p>\n

            Azelaic acid needs better delivery, not proof of efficacy<\/h2>\n\n\n\n\n\n\n\n\n\n
            Formulation realities of conventional azelaic acid<\/th>\nNanoActive™ delivery rationale<\/th>\n<\/tr>\n
            Extremely low intrinsic water solubility (\u22480.24% at 20\u00b0C)<\/td>\nNanoActive™ Azelaic Acid 50%<\/td>\n<\/tr>\n
            Historical products rely on high effective use levels<\/td>\nPURISOME\u00ae liposomal delivery \u00b7 high active payload<\/td>\n<\/tr>\n
            Risk of crystallization, recrystallization, and particles<\/td>\nImproved formulation compatibility \u00b7 lower free-crystal burden<\/td>\n<\/tr>\n
            Risk of a gritty skin feel and high solids loading<\/td>\nControlled skin and follicular delivery<\/td>\n<\/tr>\n
            Difficult to incorporate into low-viscosity, transparent modern dosage forms<\/td>\n<\/td>\n<\/tr>\n
            Limited suitability for serums and scalp formats<\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

            Delivery efficiency, not simply the concentration added.<\/b><\/p>\n

            SCIENTIFIC PRECEDENT \u00b7 PHOSPHOLIPID VESICLE DELIVERY<\/p>\n

            Vesicular delivery of azelaic acid: scientific exploration since 2004<\/h2>\n

            <\/p>\n

            As early as 2004, azelaic acid was systematically investigated in phospholipid-based vesicular systems, including liposomes and ethosomes. Vesicle morphology, particle-size distribution, and in vitro release were fully characterized.<\/p>\n

              \n
            • Characterization of phospholipid vesicle morphology and size distribution<\/li>\n
            • Franz-cell in vitro release curves<\/li>\n
            • Systematic comparison of release from liposomes and ethosomes<\/li>\n<\/ul>\n

              Phospholipid-vesicle delivery is an established scientific strategy for improving topical azelaic acid formulation and release behavior.<\/p>\n

              Esposito E, et al. Ethosomes and liposomes as topical vehicles for azelaic acid: A preformulation study. J Cosmet Sci. 2004;55:253\u2013264.<\/p>\n

              PUBLISHED PROOF OF CONCEPT \u00b7 LIPOSOMAL AZELAIC ACID<\/p>\n

              10% liposomal azelaic acid produced greater stratum corneum deposition than a conventional 20% formulation<\/h2>\n

              <\/p>\n

                \n
              • Approximate liposome diameter: 211 nm<\/li>\n
              • PDI \u2248 0.22\u20130.24, indicating a uniform distribution<\/li>\n
              • With half the active concentration, stratum corneum deposition increased 2.3\u20133.6-fold<\/li>\n<\/ul>\n

                Delivery efficiency, not simply the concentration added.<\/b><\/p>\n

                Burchacka E, et al. Biomed Pharmacother. 2016;83:771\u2013775. DOI: 10.1016\/j.biopha.2016.07.014An independently published proof-of-concept study of liposomal azelaic acid; not PURISOME\u00ae technology data.<\/p>\n

                DELIVERY TECHNOLOGY<\/p>\n

                PURISOME\u00ae FlexVes™<\/h2>\n

                A delivery system redesigned for high-payload azelaic acid<\/b><\/p>\n

                <\/p>\n

                PURISOME\u00ae is PuriPharm\u2019s proprietary nanoliposome delivery platform. Nanoscale phospholipid-bilayer vesicles carry a 50% azelaic acid payload from an aqueous environment, through the stratum corneum and follicular openings, to support local accumulation and controlled release.<\/p>\n

                01<\/p>\n

                Improved formulation compatibility<\/h3>\n

                FORMULATION<\/p>\n

                02<\/p>\n

                Optimized skin and follicular delivery<\/h3>\n

                DELIVERY<\/p>\n

                03<\/p>\n

                Sustained release<\/h3>\n

                CONTROL<\/p>\n

                04<\/p>\n

                Improved user experience with a high active load<\/h3>\n

                COMFORT<\/p>\n

                Powered by PURISOME\u00ae FlexVes™ Liposome Technology<\/p>\n

                PRODUCT PROFILE<\/p>\n

                NanoActive™ Azelaic Acid 50%<\/h2>\n

                Nano-encapsulated Azelaic Acid 50% \u00b7 Powered by PURISOME\u00ae FlexVes™ Liposome Technology<\/p>\n\n\n\n\n\n\n\n\n\n\n\n
                Product name<\/td>\nNanoActive™ Azelaic Acid 50%<\/td>\n<\/tr>\n
                INCI<\/td>\nAzelaic Acid<\/td>\n<\/tr>\n
                Active content<\/td>\n50% azelaic acid (raw-material active-payload specification)<\/td>\n<\/tr>\n
                Delivery technology<\/td>\nPURISOME\u00ae FlexVes™ Liposome Technology<\/td>\n<\/tr>\n
                Active molecule<\/td>\nAzelaic acid<\/td>\n<\/tr>\n
                Chemical class<\/td>\nSaturated C9 dicarboxylic acid<\/td>\n<\/tr>\n
                Molecular formula<\/td>\nC9H16O4<\/td>\n<\/tr>\n
                Molecular weight<\/td>\n188.22<\/td>\n<\/tr>\n
                Structural formula<\/td>\nHOOC\u2013(CH2)7\u2013COOH<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

                <\/p>\n

                Azelaic acid is a naturally occurring saturated nine-carbon dicarboxylic acid. The 50% figure is the raw material\u2019s active-content specification, not the use concentration in a finished product. Particle size, pH, recommended use level, and other technical parameters should follow the latest PuriPharm TDS.<\/p>\n

                HIGH ACTIVE PAYLOAD<\/p>\n

                50% azelaic acid active payload<\/h2>\n

                50%<\/p>\n

                AZELAIC ACID PAYLOAD<\/p>\n

                50% high active payload<\/p>\n

                \u2193<\/p>\n

                PURISOME\u00ae nano delivery<\/p>\n

                \u2193<\/p>\n

                Greater formulation freedom<\/p>\n

                50% is the active-content specification of the raw material, not the use concentration in a finished formulation.<\/p>\n

                A high-payload raw material allows formulators to deliver a meaningful azelaic acid level without introducing excessive carrier material into the finished product. This preserves valuable formulation space for refining skin feel, stability, and dosage form, leaving genuine freedom for serums, gels, emulsions, and scalp formats.<\/p>\n

                DELIVERY MECHANISM<\/p>\n

                Controlled release from the aqueous phase into the follicle<\/h2>\n

                Aqueous environment<\/p>\n

                \u2193<\/p>\n

                Nanolipid vesicles<\/p>\n

                \u2193<\/p>\n

                Stratum corneum<\/p>\n

                \u2193<\/p>\n

                Follicular opening<\/p>\n

                \u2193<\/p>\n

                Local controlled release<\/p>\n

                <\/p>\n

                Nanoscale phospholipid vesicles carry azelaic acid along the skin surface and follicular pathways, supporting local accumulation and sustained release in the target area. In this way, the delivery destination becomes part of formulation design.<\/p>\n

                BLEMISH-PRONE SKIN \u00b7 MULTI-PATHWAY CARE<\/p>\n

                Azelaic acid addresses three of the four acne pathways<\/h2>\n\n\n\n\n\n\n\n
                Pathway<\/th>\nRole<\/th>\nDescription<\/th>\n<\/tr>\n
                Follicular hyperkeratinization<\/td>\nCore action<\/td>\nRegulates keratinization and addresses the source of follicular blockage<\/td>\n<\/tr>\n
                Microbial colonization<\/td>\nCore action<\/td>\nInterferes with intracellular bacterial protein synthesis and clarifies the follicular microbiome<\/td>\n<\/tr>\n
                Inflammation \/ ROS<\/td>\nCore action<\/td>\nReduces oxidative stress and modulates inflammatory signaling<\/td>\n<\/tr>\n
                Sebum\u2013follicle environment<\/td>\nAssociated environment<\/td>\nIndirectly relates to this pathway by improving the follicular microenvironment<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

                Scientific rigor note: current literature does not support a claim that azelaic acid directly suppresses sebum secretion, so no such claim is made here. Its value lies in acting simultaneously on three core pathways: keratinization, the microbiome, and inflammatory oxidative stress.<\/p>\n

                Multi-pathway management for blemish-prone skin: a complete path from keratinization and the microbiome to inflammation and pigmentation.<\/p>\n

                COMBINATION INSPIRATION \u00b7 COMBINATION RESEARCH<\/p>\n

                Azelaic acid \u00d7 salicylic acid: clinical exploration of a multi-pathway combination<\/h2>\n\n\n\n\n\n\n\n
                Study design \u00b7 randomized controlled trial<\/th>\nPublished results<\/th>\n<\/tr>\n
                34 patients with acne \u00b7 split-face design<\/td>\nInflammatory and non-inflammatory acne lesions improved significantly on both sides<\/td>\n<\/tr>\n
                4 treatments \u00b7 2-week intervals<\/td>\nThe SA + AA side produced higher patient satisfaction and less discomfort<\/td>\n<\/tr>\n
                20% salicylic acid + 20% azelaic acid<\/td>\n<\/td>\n<\/tr>\n
                Comparator side: 25% trichloroacetic acid (TCA) chemical peel<\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

                Azelaic acid can be combined with other keratinization-regulating actives to build multi-pathway solutions for blemish-prone skin.<\/p>\n

                This was a clinical chemical-peel protocol. It is presented as scientific inspiration for combination concepts and does not constitute a cosmetic formulation recommendation or concentration guideline.<\/p>\n

                Abdel Hay R, et al. Clinical and dermoscopic evaluation of combined salicylic acid 20% and azelaic acid 20% versus trichloroacetic acid 25% chemical peel in acne: an RCT. J Dermatolog Treat. 2019;30(6):572\u2013577. DOI: 10.1080\/09546634.2018.1484876<\/p>\n

                SCALP CARE<\/p>\n

                From skin follicles to scalp follicles<\/h2>\n

                The same follicular biology also applies to the scalp. Scalp care involves more than oil control.<\/p>\n

                <\/p>\n

                Six microenvironmental concerns in scalp follicles:<\/b> keratin buildup, follicular blockage, the inflammatory environment, microbiome balance, oxidative stress, and the sebum environment.<\/p>\n

                  \n
                • Care for oily scalp \u00b7 clarifying scalp formulas<\/li>\n
                • Follicular cleansing \u00b7 acne-prone scalp<\/li>\n
                • Scalp microbiome management<\/li>\n
                • Scalp soothing and renewal<\/li>\n<\/ul>\n

                  HAIR-FOLLICLE BIOLOGY<\/p>\n

                  5\u03b1-reductase: an exploratory mechanism for scalp applications<\/h2>\n

                  Testosterone<\/p>\n

                  \u2193<\/p>\n

                  5\u03b1-Reductasepresent in human hair follicles<\/p>\n

                  \u2193<\/p>\n

                  DHT<\/p>\n

                  Published biochemical research examined the inhibitory effect of azelaic acid\u2014particularly when combined with zinc\u2014on 5\u03b1-reductase activity in human skin. This provides mechanistic scientific support for exploring scalp applications.<\/p>\n

                  Scientifically rigorous product-development language:<\/b><\/p>\n

                    \n
                  • Supports management of the follicular microenvironment<\/li>\n
                  • Research on 5\u03b1-reductase-related mechanisms provides a new scientific direction for scalp applications<\/li>\n
                  • Provides a mechanistic product-development rationale for oily-scalp and androgen-related follicular care<\/li>\n<\/ul>\n

                    Stamatiadis D, et al. Inhibition of 5\u03b1-reductase activity in human skin by zinc and azelaic acid. Br J Dermatol. 1988;119:627\u2013632.<\/p>\n

                    APPLICATION MAP<\/p>\n

                    One active for the face, body, and scalp<\/h2>\n

                    01<\/p>\n

                    FACE<\/h3>\n

                    Anti-blemish oil-control serumPore-care serumPost-acne mark repair serumBrightening serumUneven-tone careRedness-care formulaMoisturizer for oily skinClarifying cleanser<\/p>\n

                    02<\/p>\n

                    BODY<\/h3>\n

                    Back-acne careChest-acne careBody hyperpigmentation serumFollicular roughness care<\/p>\n

                    03<\/p>\n

                    SCALP<\/h3>\n

                    Clarifying scalp serumOily-scalp serumFollicular-care serumScalp keratinization careSoothing scalp productsClarifying shampooHair-root serum<\/p>\n

                    All application directions are positioned for cosmetic use. Compatibility with specific dosage forms should follow the latest PuriPharm TDS and formulation support.<\/p>\n

                    COMPARISON \u00b7 FORMULATION VALUE<\/p>\n

                    Conventional azelaic acid powder vs NanoActive™ Azelaic Acid 50%<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
                    Dimension<\/th>\nConventional azelaic acid powder<\/th>\nNanoActive™ Azelaic Acid 50%<\/th>\n<\/tr>\n
                    Aqueous-phase compatibility<\/td>\nExtremely low intrinsic water solubility (\u22480.24% at 20\u00b0C)<\/td>\nPre-engineered nanodispersion system<\/td>\n<\/tr>\n
                    Dispersion difficulty<\/td>\nRequires solubilization or suspension strategies<\/td>\nUniform dispersion and easy incorporation<\/td>\n<\/tr>\n
                    Solids loading<\/td>\nHigh use levels create a high solids load<\/td>\n50% high payload reduces formulation burden<\/td>\n<\/tr>\n
                    Crystallization management<\/td>\nFree crystalline active; recrystallization must be controlled<\/td>\nCarrier-associated active delivery<\/td>\n<\/tr>\n
                    Skin feel<\/td>\nRisk of grittiness<\/td>\nSmooth sensory profile designed for modern formats<\/td>\n<\/tr>\n
                    Delivery strategy<\/td>\nPrimarily passive diffusion<\/td>\nPURISOME\u00ae nanoliposome delivery<\/td>\n<\/tr>\n
                    Follicular delivery<\/td>\nLimited potential<\/td>\nDelivery designed for the follicular pathway<\/td>\n<\/tr>\n
                    Release behavior<\/td>\nSustained release is difficult to achieve<\/td>\nCarrier-mediated sustained release<\/td>\n<\/tr>\n
                    Formulation flexibility<\/td>\nMainly high-viscosity suspension formats<\/td>\nSerums \/ gels \/ emulsions \/ scalp formats<\/td>\n<\/tr>\n
                    Scalp suitability<\/td>\nDifficult<\/td>\nGood<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

                    KEY VALUE PROPOSITION<\/p>\n

                    Making high-concentration azelaic acid more suitable for next-generation formulations<\/h2>\n

                    01<\/p>\n

                    Multi-pathway azelaic acid biology<\/h3>\n

                    MULTI-ACTION<\/p>\n

                    02<\/p>\n

                    50% high payload<\/h3>\n

                    HIGH PAYLOAD<\/p>\n

                    03<\/p>\n

                    PURISOME\u00ae nano delivery<\/h3>\n

                    PRECISION DELIVERY<\/p>\n

                    04<\/p>\n

                    Greater freedom for modern formulations<\/h3>\n

                    FORMULATION FREEDOM<\/p>\n

                    05<\/p>\n

                    From facial blemish-prone skin to scalp-follicle care<\/h3>\n

                    SKIN + SCALP<\/p>\n

                    NanoActive™ Azelaic Acid 50%<\/b><\/p>\n

                    Powered by PURISOME\u00ae FlexVes™ Liposome TechnologyPuriPharm Co., Ltd. \u00b7 www.puriactives.com \u00b7 service@puripharm.com<\/p>\n

                    NanoActive™ Azelaic Acid 50%Powered by PURISOME\u00ae FlexVes™ Liposome TechnologyPuriPharm Co., Ltd. \u00b7 www.puriactives.com \u00b7 service@puripharm.com<\/p>\n","protected":false},"excerpt":{"rendered":"

                    ENGLISH VERSIONComplete English Article PURIPHARM CO., […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[25],"tags":[],"_links":{"self":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts\/1392"}],"collection":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1392"}],"version-history":[{"count":1,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts\/1392\/revisions"}],"predecessor-version":[{"id":1393,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts\/1392\/revisions\/1393"}],"wp:attachment":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1392"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1392"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1392"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}